Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...
Multiple system atrophy (MSA) is a sporadic and rare neurodegenerative movement disorder with an estimated annual incidence of 0.6 per 100,000 (ORPHA102) The clinical presentation is highly variable, ...
Multiple system atrophy (MSA) is often difficult to distinguish from Parkinson's disease (PD) with autonomic failure, but this is an important distinction for research studies as well as for clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback